Reports of symptomatic rebound and/or test re-positivity among COVID-19 patients following
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …

Background: In the EPIC-HR trial, nirmatrelvir plus ritonavir led to an 88% reduction in
hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …

In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2
patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced …

ABSTRACT Background In the United States, oral nirmatrelvir-ritonavir (Paxlovid™) is
authorized for use among patients aged≥ 12 years with mild-to-moderate SARS-CoV-2 …

Background The uptake of nirmatrelvir plus ritonavir (NPR) in patients with coronavirus
disease 2019 (COVID-19) has been limited by concerns around the rebound phenomenon …

Objectives The aim of this analysis was to describe nirmatrelvir/ritonavir real-world
effectiveness in preventing hospitalization among high-risk US COVID-19 patients during …

Importance Some patients treated with nirmatrelvir-ritonavir have experienced rebound of
COVID-19 infections and symptoms; however, data are scarce on whether viral rebound …

Background Nirmatrelvir is an orally administered severe acute respiratory syndrome
coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in …

Background: Efforts to understand the impact of SARS-CoV-2 variants, vaccine status, and
treatment on the development and persistence of Long COVID have intensified. Methods …

Background Nirmatrelvir/ritonavir, the first severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) protease inhibitor, reduces the risk of hospitalization and death by …